



Substitute for FORM 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number:	10/567766
Filing Date:	February 10, 2006
First Named Inventor:	HASEGAWA, Hideki
Group Art Unit:	1642
Confirmation Number:	5560
Examiner Name:	
Attorney Docket Number:	43512-103808

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	B M	3,906,092		Hilleman et al.	Sep. 16, 1975	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	B N	Butlin et al, "Naturally Occurring Double Stranded RNA and Immune Responses Part 4 Influence of Molecular Size on Antigenicity and Adjuvant Activity," <i>Eur. J. Immunol.</i> , 6(9): 607-612 (1976).		
	B O	Del Giudice, "Vaccination strategies - An overview," <i>Vac. But. Sci. Gui.</i> , 21: S83-S88 (2003).		
	B P	Holmgren et al., "Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges," <i>Vac. But. Sci. Gui.</i> , 21: S89-S95 (2003).		
	B Q	McCluskie et al., "Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants," <i>Vac. But. Sci. Gui.</i> , 19(4-5): 413-422 (1999).		
	B R	McCluskie et al., "CpG DNA as mucosal adjuvant," <i>Vaccine</i> , 18(3-4): 231-237 (1999).		
	B S	Moingeon et al., "Towards the rational design of Th1 adjuvants," <i>Vac. But. Sci. Gui.</i> , 19(31): 4363-4372 (2001).		
	B T	Knight et al., "Continued Studies on The Adjuvancy Effect of Natural and Synthetic Double Stranded RNA Preparations with Inactivated newcastle Disease Vaccines in Fowls," <i>Res. Vet. Sci.</i> , 23(1): 38-42 (1977).		
	B U	Kurstak, "Recent progress in vaccines development and new trends in immunisation," <i>Vac. But. Sci. Gui.</i> , 19(17-19): 2198-2200 (2001).		
	B V	Copy of foreign search report issued in application no. EP 04771475 (2008)		

CHDS01 SDEVADAS 477228v1

EXAMINER		DATE CONSIDERED	
----------	--	-----------------	--

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).